Guangdong Sake Biotechnology

Guangdong Sake Biotechnology is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to the discovery and development of next-generation immune cell therapies. The company's primary focus lies in engineering CAR-T and TCR-T cells to address unmet medical needs in both hematological cancers and solid tumors. Its lead candidate, SK01, is a dual-targeted CAR-T therapy designed to overcome antigen escape in B-cell malignancies. Additionally, the company is advancing TCR-T programs like SK08, which targets the NY-ESO-1 antigen in various solid tumor types. Sake Biotechnology utilizes proprietary technology platforms to enhance the persistence and anti-tumor activity of its cell therapy products.